Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/16/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 4/16/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 4/16/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| +2.41% | +0.29% | +42.02% | +71.57% | 64.69B | |
| -0.15% | +7.50% | +11.01% | +73.48% | 54.78B | |
| +0.57% | +4.60% | +10.07% | +92.86% | 53.49B | |
| +0.37% | +4.67% | +27.03% | +52.07% | 45.98B | |
| -1.21% | +2.32% | +21.80% | +123.81% | 42.94B | |
| -0.37% | +5.07% | +249.91% | +918.74% | 40.08B | |
| +0.05% | +0.21% | +18.26% | +58.53% | 33.52B | |
| -0.38% | +5.68% | +36.43% | +27.54% | 23.67B | |
| +1.19% | -4.98% | +29.01% | -0.65% | 23.97B | |
| Average | +0.25% | +2.41% | +49.51% | +157.55% | 42.57B | |
| Weighted average by Cap. | +0.39% | +2.73% | +47.57% | +158.58% |
Employees
51
